CN103622021A - Composition with auxiliary function for lowering blood lipid and auxiliary protection function for chemical liver damage - Google Patents
Composition with auxiliary function for lowering blood lipid and auxiliary protection function for chemical liver damage Download PDFInfo
- Publication number
- CN103622021A CN103622021A CN201310657044.7A CN201310657044A CN103622021A CN 103622021 A CN103622021 A CN 103622021A CN 201310657044 A CN201310657044 A CN 201310657044A CN 103622021 A CN103622021 A CN 103622021A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- protection function
- auxiliary
- chemical damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000000126 substance Substances 0.000 title claims abstract description 51
- 210000004369 blood Anatomy 0.000 title abstract description 30
- 239000008280 blood Substances 0.000 title abstract description 30
- 150000002632 lipids Chemical class 0.000 title abstract description 14
- 206010067125 Liver injury Diseases 0.000 title abstract description 8
- 231100000234 hepatic damage Toxicity 0.000 title abstract description 5
- 230000008818 liver damage Effects 0.000 title abstract description 5
- 230000006378 damage Effects 0.000 claims abstract description 48
- 244000269722 Thea sinensis Species 0.000 claims abstract description 34
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 30
- 235000020279 black tea Nutrition 0.000 claims abstract description 30
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 28
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 28
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 27
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 26
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 25
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 25
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 45
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 26
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 26
- 241000218628 Ginkgo Species 0.000 claims description 24
- 241001065361 Gynostemma Species 0.000 claims 8
- 230000000694 effects Effects 0.000 abstract description 36
- 210000004185 liver Anatomy 0.000 abstract description 23
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 15
- 230000036541 health Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 35
- 230000006870 function Effects 0.000 description 32
- 241000700159 Rattus Species 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- 229930187479 gypenoside Natural products 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 4
- HNOSJVWYGXOFRP-UNPOXIGHSA-N (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](O)C(C)(C)O)C)CC[C@@]21C HNOSJVWYGXOFRP-UNPOXIGHSA-N 0.000 description 4
- HNOSJVWYGXOFRP-UHFFFAOYSA-N Alisol A Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(O)C(C)(C)O)C)CCC21C HNOSJVWYGXOFRP-UHFFFAOYSA-N 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- -1 triterpene compounds Chemical class 0.000 description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 239000002960 lipid emulsion Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- IWQURBSTAIRNAE-UHFFFAOYSA-N Alismoxide Chemical compound CC1(O)CCC(C(C)C)=CC2C(O)(C)CCC21 IWQURBSTAIRNAE-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- 235000008718 isoliquiritigenin Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- NPZAABKZLIBPQV-FDUYOZAUSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(e,2s)-2-[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-3-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-12-hydroxy-4,4,8,10,14-pentamethyl-2, Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(C/C=C/C(C)(O)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPZAABKZLIBPQV-FDUYOZAUSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZDPDQMCPRXTLIP-PAPYEOQZSA-N Alismoxide Natural products CC(C)C1=C[C@H]2[C@@H](CC[C@]2(C)O)[C@](C)(O)CC1=O ZDPDQMCPRXTLIP-PAPYEOQZSA-N 0.000 description 1
- GBJKHDVRXAVITG-UNPOXIGHSA-N Alisol B Chemical compound O([C@@H]1[C@@H](O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C GBJKHDVRXAVITG-UNPOXIGHSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- NPZAABKZLIBPQV-UHFFFAOYSA-N Notoginsenoside A Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CC=CC(C)(O)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O NPZAABKZLIBPQV-UHFFFAOYSA-N 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000052209 Triplasis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- QMCLOHXDDPMAMI-UHFFFAOYSA-N alisol B Natural products CC(C)C(=O)C(O)CC(C)C1=C2CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC1 QMCLOHXDDPMAMI-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 239000001772 cananga odorata hook. f. and thomas. oil Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000007625 higher-energy collisional dissociation Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition with an auxiliary function for lowering blood lipid and an auxiliary protection function for chemical liver damage, and relates to the composition. The invention aims to solve the problem that the current blood lipid-lowering drug causes large damage and side effects to the liver, and is high in cost. The composition with the auxiliary function for lowering blood lipid and the auxiliary protection function for chemical liver damage is prepared from pueraria lobata, radix puerariae, pseudo-ginseng, gynostemma pentaphylla, rhizoma alismatis, folium ginkgo, semen cassiae and black tea. The prescription mainly depends on the discussion and application of the traditional Chinese medicine theory to herbal medicines and refers to modern pharmacology research materials. The prescription ingredients have a certain effect of lowering blood lipid and protecting the liver, and the prescription is reasonable and conforms to the application regulations of health food raw materials of the state food and drug administration. A preparation method of the composition is simple, and easy to operate, can control the quality, and is suitable for industrial production. The composition is applied to the field of health products.
Description
Technical field
The invention belongs to health food technology field, be specifically related to a kind of composition and method of making the same that there is auxiliary antilipemic, chemical damage is had to assistant protection function.
Background technology
Blood fat is the general name of contained lipid in blood, mainly comprise cholesterol (TC), triglycerides (being called for short TG) phosphatide and aliphatic acid etc., along with national life level improves, improper cholesterol in blood of human body (TC), triglyceride (TG), the LDL-C (LDL-C) of causing of dietary structure all obviously increases, and HDL-C (HDL-C) reduces.Along with the change of human diseases structure, the disease being caused by hyperlipidemia becomes the formidable opponent of human health gradually, and hypolipidemic also becomes medical market medicine of greatest concern.
Liver is that human body is maximum, most important removing toxic substances internal organs, and it is to having powerful defence function of detoxification from toxin external and that body self metabolism produces.In daily life, Chemical Factors, can be entered liver and be transformed by intestines and stomach, blood circulation, and therefore, liver is easily subject to the infringement of these toxicants, causes chemical damage.The health care of chemical damage focuses on prevention, and western medical treatment method mostly adopts nutrition supply and promotes the medicine of the metabolism such as lipid, sugar, protein, with liver function protecting.
Western medicine is as large to the reaction of liver renal toxicity in statins antilipemic at present, in reducing blood lipid simultaneously, also can bring other side effect, compare with Western medicine, the natural plants of integration of drinking and medicinal herbs, there is at home the applicating history of several thousand, without obvious toxic and side effect, the comprehensive human body physiological function of adjusting, transfer the total defense ability of body, can be clearing heat and detoxicating, promoting blood circulation and removing blood stasis, liver-kidney tonifying, bushing spleen, replenishing qi and blood, Synergistic, reach auxiliary antilipemic effect, in addition in auxiliary antilipemic, also reduced fat metabolism in liver, the excretion of clearing heat and detoxicating promotion noxious material, replenishing qi and blood, liver-kidney tonifying can promote the recovery of liver function, can long-term taking, prevent in early days.
Summary of the invention
The object of the invention is in order to solve existing blood lipid-lowering medicine large to liver damage, the problem that side effect is large and cost is high, and a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function is provided.
A kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function of the present invention is to be made by the root of kudzu vine of 125～375 parts, the Radix Glycyrrhizae of 125～375 parts, the pseudo-ginseng of 37～112 parts, the gynostemma pentaphylla of 125～375 parts, the rhizoma alismatis of 125～375 parts, the ginkgo leaf of 125～375 parts, the cassia seed of 125～375 parts and the black tea of 410～1240 parts by mass fraction.
The pharmacology of each bulk drug and drug effect in the present invention:
There is auxiliary antilipemic, the composition to chemical damage by assistant protection function forms with the root of kudzu vine, Radix Glycyrrhizae, pseudo-ginseng, gynostemma pentaphylla, rhizoma alismatis, ginkgo leaf, cassia seed, black tea; through retrieving tradition application and the modern chemistry pharmacological research of each constituent, show; the effect that each composition has reducing blood lipid or protects the liver, is now summarized as follows:
The root of kudzu vine
In side, the root of kudzu vine has relieving muscles to expel heat, promotes the production of body fluid, and promoting eruption, rises the effect of positive antidiarrheal, main containing triterpenes components and Coumarins compositions such as Puerarin, daidzin, daidzeins in the root of kudzu vine.The root of kudzu vine has obvious impact to the blood viscosity due to blood alcohol concentration and ethanol, can make the blood viscosity ANOMALOUS VARIATIONS due to alcohol return to normal condition by removing oxygen radical and lipoid peroxidization resistant.Improve hepatocellular energetic supersession, alleviate lipid peroxidation to hepatocellular damage, the liver of ischemical reperfusion injury is brought into play to certain protective effect; Kudzu root flavone can significantly reduce the fat that ovariectomized female rats belly is stored up, and reduces TG and TC content in ovariectomized female rats liver, thereby improves lipid-metabolism.
Radix Glycyrrhizae
In side, Radix Glycyrrhizae has and invigorates the spleen and benefits qi, clearing heat and detoxicating, expelling phlegm and arresting coughing, relieving spasm to stop pain, the effect of coordinating the drug actions of a prescription.Radix Glycyrrhizae is mainly containing triterpenes components and Celery-6 such as triterpenoid saponin glycyrrhizic acid, glycyrrhizin, flavones ingredient and alkaloid, cumarin and the polysaccharide compositions such as 8-bis--C-glucoside, licoflavone, isoliquiritigenin, glycyrrhizin, isoliquiritigenin.Liquid extract of liquorice has obvious protective effect to liver; extract of licorice root is oral, Liver Damage in Rats due to carbon tetrachloride is had to obvious protective effect; can make sex change and the degree of necrosis of liver significantly alleviate, the glycogen in liver cell and ribonucleic acid recover, and serum glutamic pyruvic transminase vigor significantly declines.Glycyrrhizin 10mg/kg every day intramuscular injection, continuous 5 days, Experimental Rabbit hyperlipidemia is had to obvious effect for reducing fat, Radix Glycyrrhizae also has solubilization in compound preparation.Glycyrrhetate (10mg/kg, oral) has the effect of norcholesterol, lipoprotein and beta lipoprotein, triglycerides to the rabbit of hyperlipemia rat and experimental atherosclerosis.
Pseudo-ginseng
In side, pseudo-ginseng has loose stasis of blood hemostasis, the effect of detumescence ding-tong, and pseudo-ginseng is mainly containing volatile oil and ginsenoside R such as γ-Java Cananga Oil alkene, sand-grass alkene
b1, R
b2, the saponin component such as notoginsenoside A, B.Pseudo-ginseng can suppress or alleviate generation and the development of atherosclerotic lesion; reduce TC and the TG content of rat; improve the HDL-C content of rat; hinder the body weight gain of hyperlipidemia model rat; arasaponin has protective effect to the Isolated Perfused Rat liver of carbon tetrachloride-injured; can make liver perfusion flow increase, reduce the GPT in perfusion, alleviate the pathology damage of liver.
Gynostemma pentaphylla
In side gynostemma pentaphylla have clearing heat and detoxicating, cough-relieving apophlegmatic, supplementing qi and nourishing yin, the effect delaying senility.The main component of gynostemma pentaphylla is gypenoside, and its aglycon is dammarane type four-ring triterpenoid, and separation obtains more than 80 kind of saponin(e so far.Gynostemma pentaphylla has significant reduction GOT and GPT effect, improve fatty liver, clinically be usually used in treating hepatitis, its remarkable effect for reducing fat is relevant with inhibition adipocyte generation free fatty and synthetic neutral fat, gypenosides has the simple cholesterol of obvious reduction and triglycerides, the effect of increasing high density lipoprotein.Gypenosides 50mg/kg can obviously suppress the rising due to the caused serum glutamic pyruvic transminase vigor of carbon tetrachloride, residual liver nuclear fission phase number showed increased under Gypenosides effect, and regeneration degree is higher than control group.The serum lipids in rats that high glucose and high fat the brings out hepatic injury that often occurs together, make glutamic-pyruvic transaminase (GPT) increase, and gypenosides can make GPT decline in lipopenicillinase.
Rhizoma alismatis
In side, rhizoma alismatis has diuresis, the effect of clearing away damp-heat.Rhizoma alismatis mainly contains the sesquiterpenoids such as monoacetate, wheat alisol A and the alisol A of alisol A, alisol B, alisol A, B, C, the triterpene compounds such as acetylate of B, C and alisol, alismoxide.The Multiple components of rhizoma alismatis is to experimental hypercholesterolemicrabbits significantly norcholesterol effect and study of anti-atherogenic effect.Rhizoma alismatis 4g/mL to rat oral gavage 2mL/ only, can obviously reduce serum total cholesterol and LDL-ch, Experimental Atherosclerotic Rabbits is had to the effect that reduces serum total cholesterol and triglycerides.Rhizoma alismatis and extract thereof have hepatoprotective effect, and the rat fat liver that Low protein diet and high lipid food are caused has antagonism, and the acute liver damage that carbon tetrachloride is caused also has protective effect.Experiment showed, that rhizoma alismatis is improved the effect of liver fat, metabolism, wherein reduce the level of triglycerides, may to improve adipose metabolism relevant with it.Pathological research shows, rhizoma alismatis can make the apparition of liver cavity sample fat alleviate.
Ginkgo leaf
In side, ginkgo leaf has and astringes the lung, and relievings asthma, promoting blood circulation and removing blood stasis, the effect of pain relieving.Main containing flavonoids and terpene lactone compound.Can significantly reduce patient's blood viscosity, improve brain blood circulation, promote neurological functional recovery, reduce the effect of triglycerides and cholesterol, rising HDL and reduction low density cholesterol (LDL).Have the effect of good protection liver cell, prevent the startup of liver fibrosis, the formation of prevention liver fibrosis, increases polyphenoils activity or content, thereby suppresses peroxidatic reaction of lipid preventing alcoholic liver injury.
Cassia seed
In side, cassia seed has removing heat to brighten vision, the effect relaxing bowel.In cassia seed, mainly contain the anthraquinone components such as archen, Physcion, aloe-emodin, Chrysophanol, Rhein and determine the naphthalene a pair of horses going side by side-pyrrones such as name glycosides.Have the total plasma cholesterol of reduction and triglycerides, reduce triglycerides and inhibition platelet aggregation in liver, anthraquinone glucosides is one of main component of its lipopenicillinase.Because it has catharsis effect, can reduce enteron aisle to the absorption of cholesterol and increase excretion, by the metabolism of feedback regulation low-density lipoprotein, thereby reduce serum cholesterol level, delay and suppress atherosclerotic plaque to form.Cassia seed water extract has weak detoxication to the mouse liver of carbon tetrachloride poisoning, and aphthopyrans ketones component has significant antagonism galactosamine to hepar damnification effect.
Black tea
Black tea outward appearance is bronzing, gives off a strong fragrance, and bitter and puckery flavor.It contains the compositions such as self peculiar theaflavin, thearubigin, terpenes, catechin, caffeine, flavonols (having the effect of strengthening capillary), saponin, GABA, fluorine, has multiple drug effect and prophylactic treatment effect.Black tea can reduce cholesterol and neutral fat, drinks black tea, can suppress the rising of blood alcohol concentration, contributes to the decomposition of alcohol.Lipometabolic effect when the caffeine in black tea has the motion of promotion, moves after picked-up caffeine, and fat metabolism meeting is more active.The pre-preventing thrombosis of flavonols in black tea generates, and the effect of prevention of cardiac is confirmed by experiment.Tea Pigment in black tea is regulating many-sided effects such as blood fat, anti peroxidation of lipid, removing oxygen radical, anti-freezing and short fibrinolytic, inhibition human aortic smooth muscle cell propagation, the formation of inhibition sustainer Lipid Plaque better.
In sum, we are with the kind root of kudzu vine to integration of drinking and medicinal herbs in traditional Chinese medicine theory, Radix Glycyrrhizae, cassia seed, and can be for the kind pseudo-ginseng of food, gynostemma pentaphylla, rhizoma alismatis, the discussion of ginkgo leaf and bread and cheese black tea, meticulous development combines with modern pharmacological research result, through function test, confirm, we have auxiliary antilipemic, the health care that chemical damage is had to auxiliary protection function, through long term toxicity test, studies confirm that this product do not find any toxic and side effect to experimental animal, show that this product is for auxiliary antilipemic, protection chemical damage is safe and effective.
The specific embodiment
The specific embodiment one: a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function of present embodiment is to be made by the root of kudzu vine of 125～375 parts, the Radix Glycyrrhizae of 125～375 parts, the pseudo-ginseng of 37～112 parts, the gynostemma pentaphylla of 125～375 parts, the rhizoma alismatis of 125～375 parts, the ginkgo leaf of 125～375 parts, the cassia seed of 125～375 parts and the black tea of 410～1240 parts by mass fraction.
Thering is auxiliary antilipemic, have the composition of assistant protection function can be prepared into tea in bag to chemical damage in present embodiment, concrete grammar is:
Get each medicinal material after cleaning respectively after pulverizer is pulverized respectively, cross respectively 20 mesh sieves, make kudzu-vine root powder, licorice powder, Radix Notoginseng powder, gynostemma pentaphyllum powder, rhizoma alismatis powder, ginkgo leaf powder, cassia seed powder, black tea powder, by prescription, take the root of kudzu vine of 125～375 parts, the Radix Glycyrrhizae of 125～375 parts, the pseudo-ginseng of 37～112 parts, the gynostemma pentaphylla of 125～375 parts, the rhizoma alismatis of 125～375 parts, the ginkgo leaf of 125～375 parts, the black tea of the cassia seed of 125～375 parts and 410～1240 parts mixes, in mixed material, add 5% PVP alcoholic solution, granulate, 79 ℃ dry, after whole grain, particle is sub-packed in filter paper bag, obtain.
Press practice of pharmacy, can also be by thering is auxiliary antilipemic in present embodiment, chemical damage is had to a kind of in the middle of the agent of composition granulation, tablet, capsule, pill of assistant protection function.Present embodiment has auxiliary antilipemic, chemical damage is had in the various formulations of composition of assistant protection function, also can add conventional drug excipient, as solvent, disintegrant, flavouring, anticorrisive agent, colouring agent etc.
In present embodiment, constituent all has reducing blood lipid and hepatoprotective effect in various degree, known this product auxiliary antilipemic, to chemical damage, has auxiliary protection function theoretical foundation abundant.Separately through the experiment of animal and human's body, confirm, this product has auxiliary antilipemic, chemical damage is had to the health care of auxiliary protection function.
The specific embodiment two: present embodiment is different from the specific embodiment one: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 150～350 parts, the Radix Glycyrrhizae of 150～350 parts, the pseudo-ginseng of 42～108 parts, the gynostemma pentaphylla of 150～350 parts, the rhizoma alismatis of 150～350 parts, the ginkgo leaf of 150～350 parts, the cassia seed of 150～350 parts and the black tea of 460～1200 parts by mass fraction.Other is identical with the specific embodiment one.
The specific embodiment three: present embodiment is different from the specific embodiment one or two: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 175～320 parts, the Radix Glycyrrhizae of 175～320 parts, the pseudo-ginseng of 50～100 parts, the gynostemma pentaphylla of 175～320 parts, the rhizoma alismatis of 175～320 parts, the ginkgo leaf of 175～320 parts, the cassia seed of 175～320 parts and the black tea of 500～1100 parts by mass fraction.Other is identical with the specific embodiment one or two.
The specific embodiment four: present embodiment is different from one of specific embodiment one to three: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 200～300 parts, the Radix Glycyrrhizae of 200～300 parts, the pseudo-ginseng of 60～90 parts, the gynostemma pentaphylla of 200～300 parts, the rhizoma alismatis of 200～300 parts, the ginkgo leaf of 200～300 parts, the cassia seed of 200～300 parts and the black tea of 550～1000 parts by mass fraction.Other is identical with one of specific embodiment one to three.
The specific embodiment five: present embodiment is different from one of specific embodiment one to four: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 210～290 parts, the Radix Glycyrrhizae of 210～290 parts, the pseudo-ginseng of 65～85 parts, the gynostemma pentaphylla of 210～290 parts, the rhizoma alismatis of 210～290 parts, the ginkgo leaf of 210～290 parts, the cassia seed of 210～290 parts and the black tea of 700～950 parts by mass fraction.Other is identical with one of specific embodiment one to four.
The specific embodiment six: present embodiment is different from one of specific embodiment one to five: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 240～270 parts, the Radix Glycyrrhizae of 240～270 parts, the pseudo-ginseng of 70～85 parts, the gynostemma pentaphylla of 240～270 parts, the rhizoma alismatis of 240～270 parts, the ginkgo leaf of 240～270 parts, the cassia seed of 240～270 parts and the black tea of 750～900 parts by mass fraction.Other is identical with one of specific embodiment one to five.
The specific embodiment seven: present embodiment is different from one of specific embodiment one to six: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 240～260 parts, the Radix Glycyrrhizae of 240～260 parts, the pseudo-ginseng of 75～85 parts, the gynostemma pentaphylla of 240～260 parts, the rhizoma alismatis of 240～260 parts, the ginkgo leaf of 240～260 parts, the cassia seed of 240～260 parts and the black tea of 800～900 parts by mass fraction.Other is identical with one of specific embodiment one to six.
The specific embodiment eight: present embodiment is different from one of specific embodiment one to seven: described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 250 parts, the Radix Glycyrrhizae of 250 parts, the pseudo-ginseng of 75 parts, the gynostemma pentaphylla of 250 parts, the rhizoma alismatis of 250 parts, the ginkgo leaf of 250 parts, the cassia seed of 250 parts and the black tea of 825 parts by mass fraction.Other is identical with one of specific embodiment one to seven.
The specific embodiment nine: a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function of present embodiment is to be made by root of kudzu vine 250g, Radix Glycyrrhizae 250g, pseudo-ginseng 75g, gynostemma pentaphylla 250g, rhizoma alismatis 250g, ginkgo leaf 250g, cassia seed 250g, black tea 825g by mass fraction.Every bag of 2.5g.
One, by the present invention of following animal experiment proof, there is auxiliary lipid-lowering function:
1, experiment purpose
Research this product has the effect of auxiliary antilipemic.
2, Experimental agents
The health food that the specific embodiment nine prepares: have auxiliary antilipemic, chemical damage had to the health products (tea in bag) of assistant protection function, No. 2 TCM Factory provides.
3, animal used as test
SPF level rat, female, Heilongjiang University of Chinese Medicine's Experimental Animal Center provides.
4, experimental technique and result
Choosing 60 of healthy SD rats, is female entirely, and first body weight 200 ± 20g carries out modeling processing.Be divided at random 6 groups, every group 10, that is: 1. Normal group, 2. hyperlipidemia model group, 3. Simvastatin group (1.5mg/kg), 4. the low dose group of pharmaceutical composition of the present invention (hereinafter to be referred as low dose group) (90mg/kg), 5. the middle dosage group of pharmaceutical composition of the present invention (hereinafter to be referred as middle dosage group) (180mg/kg), 6. the high dose group of pharmaceutical composition of the present invention (hereinafter to be referred as high dose group) is (540mg/kg).
The preparation of fat emulsion: take 15g lard and be placed in 200mL beaker, be heated to 100 ℃ of left and right it is dissolved, slowly add 6g cholesterol, be stirred to completely and dissolve; Add again 0.2g propylthiouracil (PTU) and 20mL Tween 80, fully stir evenly.In another beaker, add 65mL distilled water, be placed on electric furnace and be heated to 60 ℃, then add 2g cholate No. 3, fully stir until dissolve completely simultaneously.Then by two kinds of solution, fully mix, make fat emulsion.
The preparation of the 1%CMC solution of this composition: take this composition 1. low dose group 0.9g, 2. in dosage group 1.8g, 3. high dose group 5.4g is placed in 200mL beaker, add boiling water 100mL, be dipped to room temperature, filter, adding distil water is supplemented to 100mL, the CMC that slowly adds 1g, fully stirs evenly, and obtains.
Each group of experimental technique freely absorb normal diet adaptability and is fed after one week, model group, Simvastatin group, low dose group, middle dosage group, high dose group on this basis every morning by 10mL/kg amount gavage, give fat emulsion, last till and test end.After modeling one week, give corresponding medicine every afternoon: normal group and model group are to 1%CMC solution (lmL/100g body weight), Simvastatin group is to Simvastatin 1%CMC solution (lmL/100g body weight), basic, normal, high dosage group is given respectively the 1%CMC solution (lmL/100g body weight) of this composition of variable concentrations, successive administration 21 days, within every three days, claim 1 body weight, to adjust dosage.Each treated animal in administration after 21 days fasting can't help water 16h, pluck eyeball and get blood, separation of serum, measures serum total cholesterol (TC), serum triglyceride (TG), serum High Density Lipoprotein Cholesterol (HDL-C) and serum low-density LP cholesterol (LDL-C).
Table 1 health products of the present invention are on the result on the impact of hyperlipidemia model rat fat index
Note: with model control group comparison same period * P<0.05; * P<0.01.
Conclusion: as can be seen from Table 1, the rat to hyperlipidemia, this composition can significantly reduce serum total cholesterol (TC) and serum triglyceride (TG) content; Significantly reduce serum low-density LP cholesterol level (LDL-C), serum High Density Lipoprotein Cholesterol (HDL-C) content significantly raises.
In sum: the middle and high dosage group of auxiliary antilipemic health products of the present invention has good effect to the rat of hyperlipidemia.
Two, by the present invention of following animal experiment proof, have chemical damage had to assistant protection function:
1, experiment purpose
Research this product has chemical damage is had to auxiliary protection function
2, Experimental agents
The health food of the specific embodiment nine preparation: auxiliary antilipemic, chemical damage is had to the health products (tea in bag) of assistant protection function, No. 2 TCM Factory provides.
3, animal used as test
Kunming kind small white mouse (18-22 gram), Heilongjiang University of Chinese Medicine's Experimental Animal Center provides.
4, experimental technique and result
Choose 75 of healthy Kunming kind small white mouses (18-22 gram), establish low (0.21g/kg), in (0.42g/kg), high (1.26g/kg) three dosage groups, separately establish liver injury model group and Normal group.Tested group of distilled water leachate that gives this composition, control group and model group are drunk distilled water, and animal is weighed weekly to twice, to adjust given the test agent dosage.Continuous 30 days.The 30th day each dosage group and model group are contaminated with CCL4, dosage 24mg/kg, lumbar injection.The 31st day, 5 treated animals were plucked eyeball and are got blood, centrifugal, get serum, measured biochemical indicator: serum glutamic pyruvic transminase (GPT), glutamic-oxalacetic transaminease (GOT), white/globulin ratio (A/G); And get liver and carry out histopathologic examination.Experimental result Spss software statistics.
2, experimental result
Table 2 biochemistry detection result
* p<0.05 and CCL4 model group comparison (Analysis of variance)
From table 2, the GPT of Normal group, GOT content are starkly lower than CCL4 model group, have significant difference, and model establishment is described; With the comparison of CCL4 model group, GPT, the GOT of the basic, normal, high dosage group of tablet all obviously reduces, and it is less that low dose group reduces amplitude; , all there is significant difference in middle and high dosage group and the comparison of CCL4 model group.
Table 3 pathologic finding total mark
Table 4 pathologic finding total mark
From table 3 and table 4: Normal group has no all types of Histopathology and changes, with the comparison of ccl4 model control group, all types of average marks, grand average significant difference (P<0.05), show that chemical liver model sets up.Average mark and model control group comparison that middle and high dosage group balloon sample becomes, the average mark that significant difference (P<0.05) low dose group balloon sample becomes and model control group comparing difference be remarkable (P>0.05) not; The average mark of each dosage group endochylema cohesion and steatosis and model control group comparing difference be remarkable (P>0.05) not; Middle and high dosage group necrosis of liver cells average mark and model control group comparison, significant difference (P>0.05); Low group necrosis of liver cells average mark and the model control group comparing difference not remarkable (P>0.05) tested; Each experimental group grand average and model control group comparison, significant difference (P<0.05);
The above results shows:
1. between any one dosage group of given the test agent and model control group, in the HCDs such as that the change of balloon sample, steatosis, born of the same parents congeal is poly-, hydropic degeneration or necrosis of liver cells, necrosis of liver cells degree alleviates, difference has conspicuousness, and other pathology type and model control group are obvious, alleviate or no significant difference, can judge that zoopery pathological examination is positive.
2. between any one dosage group of given the test agent and model control group, the change of balloon sample, steatosis, endochylema condense, these four kinds of liver cell lesion types of hydropic degeneration increase the weight of and alleviate existence simultaneously, difference has conspicuousness, and necrosis of liver cells degree alleviates, and difference has conspicuousness, the score of its various pathological changes can be added, necrosis of liver cells is marked to add doubly and is counted, with total points, carry out statistical analysis, if difference has conspicuousness, can judge that zoopery pathological examination is positive.
3. result judgement: under the prerequisite of setting up at model, in ALT, two blood parameters of AST, any one and pathological examination are positive, can judge that given the test agent has auxiliary protection function to chemical damage.
Three, by the present invention of following clinical testing proof, there is auxiliary lipid-lowering function:
The composition with auxiliary lipid-lowering function (tea in bag) that the specific embodiment nine is made, chooses the patient who suffers from hyperlipidemia card and verifies, usage and dosage is: boiling water is taken after being infused in hot water or decoction, 2.5 grams/bag, each 1 bag, take 30 days cycles, 4 times on the one, result is as shown in table 4.
Table 4 has auxiliary antilipemic, chemical damage is had to the composition of assistant protection function to high fat of blood symptom patient clinical test data
As can be seen from Table 4, there is bad reaction in none example of 15 routine hyperlipidemia patients, and after 30 days, symptom all alleviates.Illustrate that the composition with auxiliary lipid-lowering function that the specific embodiment nine makes is good to the result for the treatment of of hyperlipemia symptom.
Each raw material synergistic application of this compound, has clearing heat and detoxicating, promoting blood circulation and removing blood stasis, liver-kidney tonifying, bushing spleen, replenishing qi and blood, the effect of Synergistic, finished product adopts modern preparation process, under rational method of quality control and strict management of product measure, make steady quality, taking convenience.This product meets the requirement of State Food and Drug Administration to health food, safe and effective, can long-term taking, and be high fat of blood, health food that chemical damage patient is desirable.
Claims (8)
1. have auxiliary antilipemic, chemical damage had to the composition of assistant protection function, it is characterized in that having auxiliary antilipemic, chemical damage being had to the composition of assistant protection function is to be made by the root of kudzu vine of 125～375 parts, the Radix Glycyrrhizae of 125～375 parts, the pseudo-ginseng of 37～112 parts, the gynostemma pentaphylla of 125～375 parts, the rhizoma alismatis of 125～375 parts, the ginkgo leaf of 125～375 parts, the cassia seed of 125～375 parts and the black tea of 410～1240 parts by mass fraction.
2. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 1, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 150～350 parts, the Radix Glycyrrhizae of 150～350 parts, the pseudo-ginseng of 42～108 parts, the gynostemma pentaphylla of 150～350 parts, the rhizoma alismatis of 150～350 parts, the ginkgo leaf of 150～350 parts, the cassia seed of 150～350 parts and the black tea of 460～1200 parts by mass fraction.
3. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 2, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 175～320 parts, the Radix Glycyrrhizae of 175～320 parts, the pseudo-ginseng of 50～100 parts, the gynostemma pentaphylla of 175～320 parts, the rhizoma alismatis of 175～320 parts, the ginkgo leaf of 175～320 parts, the cassia seed of 175～320 parts and the black tea of 500～1100 parts by mass fraction.
4. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 3, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 200～300 parts, the Radix Glycyrrhizae of 200～300 parts, the pseudo-ginseng of 60～90 parts, the gynostemma pentaphylla of 200～300 parts, the rhizoma alismatis of 200～300 parts, the ginkgo leaf of 200～300 parts, the cassia seed of 200～300 parts and the black tea of 550～1000 parts by mass fraction.
5. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 4, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 210～290 parts, the Radix Glycyrrhizae of 210～290 parts, the pseudo-ginseng of 65～85 parts, the gynostemma pentaphylla of 210～290 parts, the rhizoma alismatis of 210～290 parts, the ginkgo leaf of 210～290 parts, the cassia seed of 210～290 parts and the black tea of 700～950 parts by mass fraction.
6. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 5, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 240～270 parts, the Radix Glycyrrhizae of 240～270 parts, the pseudo-ginseng of 70～85 parts, the gynostemma pentaphylla of 240～270 parts, the rhizoma alismatis of 240～270 parts, the ginkgo leaf of 240～270 parts, the cassia seed of 240～270 parts and the black tea of 750～900 parts by mass fraction.
7. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 6, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 240～260 parts, the Radix Glycyrrhizae of 240～260 parts, the pseudo-ginseng of 75～85 parts, the gynostemma pentaphylla of 240～260 parts, the rhizoma alismatis of 240～260 parts, the ginkgo leaf of 240～260 parts, the cassia seed of 240～260 parts and the black tea of 800～900 parts by mass fraction.
8. a kind of composition that has auxiliary antilipemic, chemical damage is had to assistant protection function according to claim 7, is characterized in that described having auxiliary antilipemic, chemical damage is had to the composition of assistant protection function is to be made by the root of kudzu vine of 250 parts, the Radix Glycyrrhizae of 250 parts, the pseudo-ginseng of 75 parts, the gynostemma pentaphylla of 250 parts, the rhizoma alismatis of 250 parts, the ginkgo leaf of 250 parts, the cassia seed of 250 parts and the black tea of 825 parts by mass fraction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310657044.7A CN103622021A (en) | 2013-12-09 | 2013-12-09 | Composition with auxiliary function for lowering blood lipid and auxiliary protection function for chemical liver damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310657044.7A CN103622021A (en) | 2013-12-09 | 2013-12-09 | Composition with auxiliary function for lowering blood lipid and auxiliary protection function for chemical liver damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103622021A true CN103622021A (en) | 2014-03-12 |
Family
ID=50203752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310657044.7A Pending CN103622021A (en) | 2013-12-09 | 2013-12-09 | Composition with auxiliary function for lowering blood lipid and auxiliary protection function for chemical liver damage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103622021A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104473148A (en) * | 2014-11-10 | 2015-04-01 | 浙江大学 | Health food with auxiliary blood fat reducing effect |
| CN106578185A (en) * | 2015-10-19 | 2017-04-26 | 屈涛 | Jiangjunhong blood fat lowering tea and preparation method thereof |
| CN112494626A (en) * | 2020-12-23 | 2021-03-16 | 杭州胡庆余堂天然食品有限公司 | Tablet with protective effect on chemical liver injury and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110151A (en) * | 1994-04-07 | 1995-10-18 | 任贵兴 | Antialcoholic liver-protecting preparation and its preparing method |
| KR20100022128A (en) * | 2008-08-13 | 2010-03-02 | (주)한중보건연구원 | Bow band function |
| CN102008598A (en) * | 2010-12-17 | 2011-04-13 | 深圳技师学院 | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation |
| CN102423381A (en) * | 2011-12-30 | 2012-04-25 | 苏州爱斯欧蒂生物科技有限公司 | Health tea with fat-reducing efficacy |
| CN102727680A (en) * | 2012-06-21 | 2012-10-17 | 长春康彼达科技有限公司 | Traditional Chinese medicine for reducing blood fat, and preparation method thereof |
-
2013
- 2013-12-09 CN CN201310657044.7A patent/CN103622021A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110151A (en) * | 1994-04-07 | 1995-10-18 | 任贵兴 | Antialcoholic liver-protecting preparation and its preparing method |
| KR20100022128A (en) * | 2008-08-13 | 2010-03-02 | (주)한중보건연구원 | Bow band function |
| CN102008598A (en) * | 2010-12-17 | 2011-04-13 | 深圳技师学院 | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation |
| CN102423381A (en) * | 2011-12-30 | 2012-04-25 | 苏州爱斯欧蒂生物科技有限公司 | Health tea with fat-reducing efficacy |
| CN102727680A (en) * | 2012-06-21 | 2012-10-17 | 长春康彼达科技有限公司 | Traditional Chinese medicine for reducing blood fat, and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104473148A (en) * | 2014-11-10 | 2015-04-01 | 浙江大学 | Health food with auxiliary blood fat reducing effect |
| CN106578185A (en) * | 2015-10-19 | 2017-04-26 | 屈涛 | Jiangjunhong blood fat lowering tea and preparation method thereof |
| CN112494626A (en) * | 2020-12-23 | 2021-03-16 | 杭州胡庆余堂天然食品有限公司 | Tablet with protective effect on chemical liver injury and preparation method thereof |
| CN112494626B (en) * | 2020-12-23 | 2022-03-11 | 杭州胡庆余堂天然食品有限公司 | Tablet with protective effect on chemical liver injury and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104906406B (en) | A kind of natural drug composition and preparation method for preventing and treating alcoholic liver injury | |
| CN104083727A (en) | Traditional Chinese medicine composition for nourishing and protecting liver | |
| CN102188513A (en) | Medical composition with auxiliary protection function for chemical liver damage | |
| CN101637492B (en) | Preparation method of total flavonoids in persimmon leaves | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN102579836B (en) | Traditional Chinese medical dendrobium huoshanense composition and preparation method thereof | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN103622021A (en) | Composition with auxiliary function for lowering blood lipid and auxiliary protection function for chemical liver damage | |
| CN103372073A (en) | Red rice and hawthorn medicinal composition for regulating blood fat and preparation method of composition | |
| CN105918946A (en) | Red date and Chinese wolfberry fruit liver tonifying composition, granules and preparation method thereof | |
| CN103142848B (en) | Anti-aging Chinese medicine preparation and preparation method thereof | |
| CN110876772A (en) | Preparation method and application of traditional Chinese medicine preparation with liver protection function | |
| CN100551396C (en) | A kind of Chinese patent medicine for the treatment of fatty liver and preparation method thereof | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN101073602B (en) | Medicinal composition for treating or improving liver function, its production and use | |
| CN103372040B (en) | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof | |
| CN1795901B (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition | |
| CN103877513A (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof | |
| CN106578185A (en) | Jiangjunhong blood fat lowering tea and preparation method thereof | |
| CN104257839A (en) | Traditional Chinese medicine composition with effects of reducing blood glucose and blood fat and protecting vascular endothelium and preparation method thereof | |
| CN104127826A (en) | Traditional Chinese medicine composition for treating chronic alcoholic liver disease | |
| CN106390034A (en) | Traditional Chinese medicine compound preparation for curing 2-diabetes | |
| CN103285110B (en) | Traditional Chinese medicine for treating hyperlipidemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140312 |